title: Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome.
abstract: Ninety nine patients with 101 bacteraemic episodes due to Ps. aeruginosa (PA) within 6 years were divided into two groups according to their resistance to imipenem-91 due to imipenem sensitive (ISPA) and 10 due to resistant (IRPA). Risk factors, the clinical course and the outcome were evaluated and compared. Acute leukaemia, prolonged neutropenia, previous therapy with amikacin, third generation of cephalosporins, imipenem and prophylaxis by quinolones were significantly more frequently associated with IRPA. Imipenem resistant PA bacteraemia were associated with higher incidence of septic shock (40% vs 19.8%, p < 0.02) and death (33.3%) than ISPA bacteraemias. Since 1992, when first IRPA appeared, the incidence of imipenem resistance increased tenfold, and in 1994, up to 10% of PA causing bloodstream infections in cancer patients in our center were imipenem resistant. (Tab. 3, Ref. 8.).
authors.affiliation: Department of Medicine, Tyrnaviensis University, Trnava, Bratislava.
authors.forename: V
authors.initials: V
authors.lastname: Krcméry
authors.forename: J
authors.initials: J
authors.lastname: Trupl
authors.forename: A
authors.initials: A
authors.lastname: Kunová
authors.forename: S
authors.initials: S
authors.lastname: Spánik
authors.forename: I
authors.initials: I
authors.lastname: Ilavská
authors.forename: L
authors.initials: L
authors.lastname: Hel'pianska
authors.forename: I
authors.initials: I
authors.lastname: Bezáková
authors.forename: L
authors.initials: L
authors.lastname: Drgona
authors.forename: E
authors.initials: E
authors.lastname: Oravcová
authors.forename: M
authors.initials: M
authors.lastname: Studená
authors.forename: J
authors.initials: J
authors.lastname: Lacka
authors.forename: L
authors.initials: L
authors.lastname: Sevcíková
authors.forename: P
authors.initials: P
authors.lastname: Koren
authors.forename: E
authors.initials: E
authors.lastname: Kukucková
authors.forename: K
authors.initials: K
authors.lastname: Stopková
authors.forename: I
authors.initials: I
authors.lastname: Krupová
authors.forename: S
authors.initials: S
authors.lastname: Grausová
authors.forename: J
authors.initials: J
authors.lastname: Svec
mesh_terms: D000328:Adult; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D004352:Drug Resistance, Microbial; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications*; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012189:Retrospective Studies; D012307:Risk Factors; D013845:Thienamycins / Q000627:therapeutic use*
chemical_list: D013845:Thienamycins; D015378:Imipenem